• Jeroen Rovers MD, PhD joins DCprime as Chief Medical Officer 12 October, 2018     Jeroen Rovers MD, PhD joins DCprime as Chief Medical Officer Leiden, The Netherlands, October 01, 2018 – DCprime announces today that Jeroen Rovers MD, PhD joins the company as its Chief Medical Officer with immediate effect. Jeroen trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 15 years ... Read more
  • Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy 26 July, 2018     Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy. Leiden, The Netherlands, 26 July 2018 – DCprime announces that the results of the phase I study with its lead product DCP-001 in AML have been published in Cancer Immunology, Immunotherapy. The phase I study was ... Read more
  • DCprime and Glycotope announce licensing agreement and collaboration 18 July, 2018     DCprime and Glycotope announce licensing agreement and collaboration Leiden, The Netherlands, and Berlin, Germany, 18 July 2018 – DCprime bv, a clinical stage biotechnology company focused on cell-based cancer vaccines, and Glycotope GmbH, a clinical stage immuno-oncology company built on world-leading glycobiology expertise, announce today that they have entered into a license agreement and research collaboration. Under ... Read more
  • DCprime announces that Erik Manting PhD will join the company as its CEO 1 March, 2018 Leiden, The Netherlands, March 01, 2018 – DCprime announces today that Erik Manting PhD will become DCprime’s new Chief Executive Officer with immediate effect. Dr Manting succeeds Ada Kruisbeek, who will remain committed to DCprime as Chief Scientific Officer. Prior to joining DCprime, Erik spent 15 years in different management and commercial roles, of which ... Read more
  • DCOne® induces immune responses against Multiple Myeloma 16 November, 2017 Leiden, The Netherlands – DCPrime B.V., a clinical stage company dedicated to developing cancer vaccines based on its proprietary DCOne® platform, announces the publication of a peer-reviewed research paper which documents that its lead product DCP-001 can induce T cell activation and myeloma-specific immunity in peripheral blood mononuclear cells from patients with Multiple Myeloma (MM). ... Read more
  • DCPrime and apceth Biopharma GmbH announce manufacturing partnership 14 November, 2017 Leiden, The Netherlands, and Munich, Germany – DCPrime BV, a clinical stage company developing dendritic cell vaccines to treat cancer, and apceth Biopharma GmbH, an established contract manufacturing organization in the field of gene and cell therapy, report today that they have entered into a strategic manufacturing agreement. The collaboration involves clinical batch production and ... Read more
  • DCPrime obtains patent protection for DCOne® platform 2 November, 2016 DCPrime obtains broad patent protection in the EU for proprietary DCOne® platform. DCPrime, a clinical stage cancer immunotherapy company, has been granted a European patent on its DCOne® platform. The patent covers its proprietary cell line DCOne®, the accompanying methods for obtaining mature dendritic cells, and the mature dendritic cells which are obtainable by this method, ... Read more
  • DCPrime and VUmc awarded €6 million Euro Horizon2020 grant 28 January, 2016 DCPrime and VUmc awarded Horizon2020 grant to support the development of a dendritic-cell vaccine therapy for Acute Myeloid Leukemia. DCPrime, a Dutch cancer immunotherapy company, and the Department of Hematology of the VU medical center in Amsterdam, announce that, together with a strong international consortium of academic and company partners, they have been awarded a 6 million ... Read more
  • DCPrime and Dana Farber Cancer Center start collaboration on cancer immunotherapy treatment of Multiple Myeloma 25 August, 2015 Leiden, The Netherlands – Dutch clinical stage company DCPrime BV, dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne®, today announced that it has started a collaboration on the potential application of its lead product DCP-001 in Multiple Myeloma patients with Prof. Dr. David Avigan, Beth Israel Deaconess Medical Center, Dana ... Read more
  • DCPrime granted €1.2 million government loan for development of its lead product in novel indications 9 July, 2015 Leiden, The Netherlands – DCPrime, a clinical stage company dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne®, today announced that the Dutch Ministry of Economic Affairs, via its agency RVO (Rijksdienst voor Ondernemend Nederland), will support DCPrime B.V. for extending the applications of its lead product DCP-001 to other hematological ... Read more

DCprime news flashes before 2014.